Strides Pharma Science Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹452.75
- Today's High:
- ₹476.25
- Open Price:
- ₹472.45
- 52W Low:
- ₹268.4
- 52W High:
- ₹392.2
- Prev. Close:
- ₹471.95
- Volume:
- 45785
Company Statistics
- Market Cap.:
- ₹33.56 billion
- Book Value:
- 282.187
- Revenue TTM:
- ₹28.48 billion
- Operating Margin TTM:
- 13.87%
- Gross Profit TTM:
- ₹15.53 billion
- Profit Margin:
- 4.78%
- Return on Assets TTM:
- 3.31%
- Return on Equity TTM:
- 0%
Company Profile
Strides Pharma Science Ltd had its IPO on under the ticker symbol STAR.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Strides Pharma Science Ltd has a staff strength of 0 employees.
Stock update
Shares of Strides Pharma Science Ltd opened at ₹472.45 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹452.75 - ₹476.25, and closed at ₹456.75.
This is a -3.22% slip from the previous day's closing price.
A total volume of 45,785 shares were traded at the close of the day’s session.
In the last one week, shares of Strides Pharma Science Ltd have increased by +3.02%.
Strides Pharma Science Ltd's Key Ratios
Strides Pharma Science Ltd has a market cap of ₹33.56 billion, indicating a price to book ratio of 1.4095 and a price to sales ratio of 0.9481.
In the last 12-months Strides Pharma Science Ltd’s revenue was ₹28.48 billion with a gross profit of ₹15.53 billion and an EBITDA of ₹5.48 billion. The EBITDA ratio measures Strides Pharma Science Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Strides Pharma Science Ltd’s operating margin was 13.87% while its return on assets stood at 3.31% with a return of equity of 0%.
In Q4, Strides Pharma Science Ltd’s quarterly earnings growth was a positive 2719.5% while revenue growth was a positive 14%.
Strides Pharma Science Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 24.5899
- PEG
Its diluted EPS in the last 12-months stands at ₹15.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Strides Pharma Science Ltd’s profitability.
Strides Pharma Science Ltd stock is trading at a EV to sales ratio of 1.6497 and a EV to EBITDA ratio of -664.4477. Its price to sales ratio in the trailing 12-months stood at 0.9481.
Strides Pharma Science Ltd stock pays annual dividends of ₹2 per share, indicating a yield of 0.55% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹68.45 billion
- Total Liabilities
- ₹33.05 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Strides Pharma Science Ltd ended 2024 with ₹68.45 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹68.45 billion while shareholder equity stood at ₹23.31 billion.
Strides Pharma Science Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹33.05 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹5.00 billion in goodwill. Its cash balance stood at ₹1.11 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹9.43 billion.
Strides Pharma Science Ltd’s total current assets stands at ₹32.54 billion while long-term investments were ₹0 and short-term investments were ₹6.03 billion. Its net receivables were ₹11.99 billion compared to accounts payable of ₹9.67 billion and inventory worth ₹11.34 billion.
In 2024, Strides Pharma Science Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Strides Pharma Science Ltd paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹456.75
- 52-Week High
- ₹392.2
- 52-Week Low
- ₹268.4
- Analyst Target Price
- ₹
Strides Pharma Science Ltd stock is currently trading at ₹456.75 per share. It touched a 52-week high of ₹392.2 and a 52-week low of ₹392.2. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹443.36 and 200-day moving average was ₹363.94 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2971% of the company’s stock are held by insiders while 3942.4% are held by institutions.
Frequently Asked Questions About Strides Pharma Science Ltd
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australasia, North America, Europe, Asia, India, and internationally. The company offers pharma generics, including tablets, hard and soft gelatin capsules, sachets, oral liquids, and powders, as well as semi solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Clavicin, Combiart, Solcer, Melonax, Duotab, and Vitafer brands; and drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was founded in 1990 and is headquartered in Bengaluru, India.